HAMLET Pharma will be in the spotlight in the Italian national TV Rai 3 Friday April 7 at 2:50 pm

HAMLET Pharma will be in the spotlight in the Italian national TV Rai 3 Friday April 7 at 2:50 pm. The host will be the famous scientific program TGR Leonardo. The study is covering the connection between the breast milk and HAMLET cancer therapy, a long road of research achieved remarkable results over different types of cancer

The program TGR Leonardo covers science and technology as well as related topics relevant to health, environmental issues, economy and social change. The channel is a major force in spreading new knowledge to the public and has has grown in importance during 15 years of broadcasting.  Watch it live on our website  Hamletpharma.com

Summary about HAMLET pharma in the program

Professor Catharina Svanborg is an invited speaker at the 12th International Breastfeeding and Lactation Symposium conference hosted by Professor Moro and starting on 8 April 2017. The lecture will cover the HAMLET discovery, research on the molecular characteristics of the complex, the mechanisms of tumor cell death and the effects of HAMLET in patients and tumor models. The media interest was created by an article about HAMLET, published in an Italian Journal. The conference organizers have been contacted by a number of journalists and a press conference will be held on April 8th. The paper will be published in the Italian journal on the 10/04/2017 the journal Annali dell'Istituto Superiore di Sanità (established in 1938).

HAMLET - from serendipity to the clinic

The discovery of HAMLET is a fascinating example of the versatility of the protective potential of human milk. HAMLET shows broad efficiency against different types of tumor cells and a high degree of tumor specificity. Our methodology has made it possible to demonstrate treatment effects of HAMLET in animal models and clinical studies. HAMLET offers a new vision for the improvement of cancer prevention and more cancer-specific therapies. New cancer therapies need to be selective and efficient and HAMLET has shown both of these characteristics. 

 Recently, a detailed chemical analysis identified a smaller part of the HAMLET molecule that can be produced synthetically, and we are exploring this as a new drug candidate. The next steps will entail producing industrial-scale quantities of HAMLET, fulfilling all of the regulatory and toxicological requirements for drug development, and undertaking extensive clinical trials. Ultimately, we hope that these efforts will offer new treatment for cancer patients, who currently lack effective therapies.

Considering HAMLET’s chance beginning as an antibacterial fraction in human milk, the project has come a long way.

For more details visit our website

April newsletter 04/17

HAMLETpharma.com 

For more information, please contact

Catharina Svanborg, Chairman of the board, Hamlet Pharma, +46-709 42 65 49

Catharina.svanborg@med.lu.se

Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57

mats.persson@hamletpharma.com  

About Hamlet Pharma

Hamlet Pharma AB owns and develops a new technology to kill cancer cells without harming healthy tissues. The HAMLET technology is focused around the HAMLET family of tumoricidal protein-lipid complexes, formed by naturally occurring molecules from human milk and extended to include recombinant variants of the natural substance. HAMLET has validated therapeutic efficacy in clinical studies and animal models, and in many different cellular models of human cancer. HAMLET will now be developed further for Phase II clinical trials, to verify the positive proof of concept studies. Hamlet Pharma AB shares are listed at AktieTorget. HAMLET is an abbreviation for Human Alpha-lactalbumin Made LEthal to Tumor cells.

Subscribe

Documents & Links